An interventional study of Green tea (Camellia sinensis) 1000 mg as extract and Placebo in Female, Older Adults and Sarcopenia, sponsored by University of Valladolid. Recruiting at 1 site in Spain. Open to female participants aged 60 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-05.
Sponsored by University of Valladolid · Not applicable, Interventional, and Treatment
Among 99 studies in Sarcopenia with a site in Spain — 33 open to participants now, 40 under way, none of them phase 3. Sarcopenia · Spain.
Among the 99 studies in Sarcopenia with a site in Spain, this one is the 21st largest by planned enrollment of the 77 interventional ones that give a count, is one of 14 that started in 2024, is one of 70 with no phase, reaches primary completion later than 3 of the 39 other live ones, and was the 60th registered.
1,329 studies on the registry are indexed under Sarcopenia; 420 are open to participants now.
Browse Sarcopenia studies →33 of the 99 studies in Sarcopenia with a site in Spain are open now. Recruiting first, the newest first:
University of Valencia · Sites in Spain
Universidad de Granada · Sites in Spain
University of Salamanca · Sites in Spain
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Sites in Spain
Sara Casanova Prieto · Sites in Spain
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 33 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.
This study: 60 Years to 80 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 14 started in 2024.
This study's planned enrollment of 120 is above the median of 60 across 855 interventional studies indexed under Sarcopenia.
Median enrollment 72 across the 77 interventional studies, 156 across the 22 observational. Of the 48 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 99 have an industry lead sponsor. The 10 most frequent:
University of Valladolid is the lead sponsor of 34 studies on the registry; 9 are open to participants now.
University of Valladolid has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
15 of the studies in Sarcopenia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387770University of SalamancaMuscle Deterioration in Hospitalized Cancer Patient | 2026-11-30 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
| NCT06634316Maimónides Biomedical Research Institute of CórdobaSarcopenia in Patients With Heart Failure | 2026-12-31 |
| NCT07447375University of SalamancaExercise During Hemodialysis: Impact on Sarcopenia and Sleep Quality | 2026-12-31 |
| NCT06015971Maimónides Biomedical Research Institute of CórdobaOmega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer | 2026-12-31 |
Among the 99 studies in Sarcopenia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Introduction: One of the consequences of aging is the decrease in physical performance which can affect the quality of life of older people. Although physical exercise is beneficial in improving this problem, older women do not seem to benefit as much as men. In this sense, the use of ergonomic aids by women could compensate for these issues. Thus, green tea has shown beneficial effects on physical performance in athletes through, among others, improving blood flow and vasodilation, mitochondrial respiration, calcium management, glucose and amino acid uptake, lipid oxidation, modulation of muscle damage, antioxidant effect, and anabolic and catabolic hormones, activation of the hypothalamic-pituitary-adrenal axis, etc. Therefore, the deterioration of physical performance and quality of life of green tea.
Objective: To analyze the effect of supplementation with 1 g/day green tea extract (500 mg of polyphenols) for 10 weeks on quality of life values, physical performance (grip strength, walking speed, and resistance), and health biomarkers (biochemical, hematological, and hormonal) in women over 60 years of age who follow a physical training program.
Methods: A total of 20 female volunteers between 60 and 73 years old (age: 65.9±4.58 years, BMI: 25.09±3.24 and body fat percentage: 32.54±6.39) who followed a physical activity adapted to their age and abilities are the members of this study. The volunteers were divided into two groups: placebo (CG; n = 10) and supplemented with 1 g/day of green tea (GI; n = 10). Different physical tests were performed (grip strength, walking speed and resistance) and the quality of life questionnaire (WHOQOL-BREF) was passed and health biomarkers (biochemical, hematological, and hormonal) were analyzed at the beginning (T1) and at the end of the 10 weeks of intervention (T2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 capsules for 10 consecutive weeks, distributed in a single daily oral intake with the main meal
Dietary Supplement: Green tea (Camellia sinensis) 1000 mg as extract
2 capsules for 10 consecutive weeks, distributed in a single daily oral intake with the main meal
Other: Placebo
Two capsules per day; Each capsule includes Green Tea Leaf (Camellia sinensis) 5000 mg composed of 500 mg of green tea extract and 250 mg of polyphenols (epicatechin (EC), epigallocatechin (EGC), epicatechin gallato (ECG), and epigallocatechin gallato (EGCG))
Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Green tea tablets to ensure blinding.
Creatine kinase (CK)
CK is an enzyme expressed by various tissues and cell types; markers of muscle damage
Time frame: first day of study and after 30 days of supplementation (end of study)
Lactate dehydrogenase (LDH)
LDH is a catalytic enzyme found in many tissues of the body;markers of muscle damage
Time frame: first day of study and after 30 days of supplementation (end of study)
Myoglobin (Mb)
Mb is a muscle heteroprotein
Time frame: 1st and 30th days of the trial
Alanine Aminotransferase (ALT)
markers of liver damage
Time frame: 1st and 30th days of the trial
Aspartate Aminotransferase (AST)
markers of liver damage
Time frame: 1st and 30th days of the trial
Interleukin 6 (IL-6)
inflammatory marker
Time frame: 1st and 30th days of the trial
C-reactive protein (PCR)
inflammatory marker
Time frame: 1st and 30th days of the trial
Testosterone
hormonal marker
Time frame: 1st and 30th days of the trial
Cortisol
hormonal marker
Time frame: 1st and 30th days of the trial
Miostatin (GDF8)
growth factor that limits the growth of muscle tissue
Time frame: 1st and 30th days of the trial
advanced oxidation protein products (AOPP)
amino acid oxidation marker
Time frame: 1st and 30th days of the trial
lipid peroxidation (LPO)
lipid oxidation marker
Time frame: 1st and 30th days of the trial
Oxygen radical absorption (ORAC)
antioxidant strength marker
Time frame: 1st and 30th days of the trial
Total antioxidant status (TAS)
antioxidant capacity marker
Time frame: 1st and 30th days of the trial
Total antioxidant capacity (TAC)
antioxidant capacity marker
Time frame: 1st and 30th days of the trial
Short Physical Performance Battery (SPPB)
Test evaluates three aspects of mobility
Time frame: 1st and 30th days of the trial
World Health Organization Quality of Life - BREF (WHOQOL-BREF)
a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment
Time frame: 1st and 30th days of the trial
Start is estimated for Mar 2024; primary completion for Dec 2024, 9 months later.
Of 492 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 9 months is below that.
Counting every sponsor, half of 503 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tea
University of Valladolid